HEALIOS K.K. Logo

HEALIOS K.K.

Develops iPS and somatic stem cell therapies for diseases like ARDS and cancer.

4593 | T

Overview

Corporate Details

ISIN(s):
JP3835100003
LEI:
Country:
Japan
Address:
千代田区有楽町一丁目7番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Healios K.K. is a biotechnology company specializing in the research, development, and manufacturing of cell therapy and regenerative medicine products. A pioneer in the field, the company develops treatments for diseases with high unmet medical needs by leveraging induced pluripotent stem (iPS) cell technology and somatic stem cells. Its core R&D focuses on creating therapies from iPS cell-derived products, including retinal pigment epithelium (RPE) cells and Natural Killer (NK) cells for cancer immunotherapy. The company's pipeline also features somatic stem cell products like HLCM051 (MultiStem) for treating conditions such as acute respiratory distress syndrome (ARDS). Healios utilizes proprietary gene editing technology to develop next-generation universal donor cells, aiming to overcome immune rejection and broaden the application of cellular medicine.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-13 05:35
Report Publication Announcement
確認書
Japanese 8.2 KB
2025-08-13 05:34
Interim Report
半期報告書-第15期(2025/01/01-2025/12/31)
Japanese 436.9 KB
2025-05-13 08:33
Regulatory News Service
臨時報告書
Japanese 19.7 KB
2025-03-27 07:22
Post-Annual General Meeting Information
臨時報告書
Japanese 25.4 KB
2025-03-27 07:21
Registration Form
確認書
Japanese 8.1 KB
2025-03-27 07:20
Governance Information
内部統制報告書-第14期(2024/01/01-2024/12/31)
Japanese 21.7 KB
2025-03-27 07:19
Annual Report
有価証券報告書-第14期(2024/01/01-2024/12/31)
Japanese 2.0 MB
2025-02-14 05:13
Share Issue/Capital Change
訂正臨時報告書
Japanese 37.5 KB
2025-02-14 04:07
Regulatory News Service
臨時報告書
Japanese 21.3 KB
2025-01-27 07:31
Registration Form
有価証券届出書(参照方式)
Japanese 224.3 KB
2025-01-22 07:33
Share Issue/Capital Change
臨時報告書
Japanese 53.3 KB
2024-11-13 07:34
Regulatory News Service
臨時報告書
Japanese 20.0 KB
2024-08-13 08:04
Regulatory News Service
臨時報告書
Japanese 19.9 KB
2024-08-13 08:04
Report Publication Announcement
確認書
Japanese 8.2 KB
2024-08-13 08:03
Interim Report
半期報告書-第14期(2024/01/01-2024/12/31)
Japanese 402.0 KB

Automate Your Workflow. Get a real-time feed of all HEALIOS K.K. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HEALIOS K.K.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HEALIOS K.K. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Enorama Pharma AB Logo
Develops & makes consumer nicotine products & medicated gums, offering private label solutions.
Sweden
ERMA
Ensysce Biosciences, Inc. Logo
Developing safer opioids with abuse-deterrent and overdose protection technology for severe pain.
United States of America
ENSC
Entera Bio Ltd. Logo
Developing oral versions of injectable drugs for osteoporosis, hypoparathyroidism, and obesity.
United States of America
ENTX
Entero Therapeutics, Inc. Logo
Develops targeted oral therapies for a range of gastrointestinal (GI) diseases.
United States of America
ENTO
Entrada Therapeutics, Inc. Logo
Developing intracellular therapeutics for rare neuromuscular diseases via its EEV™ platform.
United States of America
TRDA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea
183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden
ENZY
Developing alopecia therapies, skin regeneration products, and preclinical CRO services.
South Korea
446440
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden
EQL
Equillium, Inc. Logo
Clinical-stage biotech creating therapies for severe autoimmune and inflammatory disorders.
United States of America
EQ

Talk to a Data Expert

Have a question? We'll get back to you promptly.